Clinical Trial Update: A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051 [Phase 1]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1 study evaluating safety, tolerability, pharmacokinetics and immunogenicity of co-administered MER…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Middle East Respiratory Syndrome

Drugs mentioned

• REGN3048 (REGN3048)
• REGN3051 (REGN3051)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Corona Virus Infection | Phase 1 | Status: COMPLETED